Skip to main content
. Author manuscript; available in PMC: 2023 Oct 3.
Published in final edited form as: JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974

Table 3.

Vaccine Efficacy Results of Clinical Trials

Clinical trial, VE, estimate (95% CI)
End pointa COVE AZD1222 ENSEMBLE PREVENT-19 VAT00008 (stage 2)
Primary analysis
 Primary VE 94.1 (89.3–96.8) 74.0 (65.3–80.5) 66.9 (59.0–73.4) 90.4 (82.9–94.6) 64.7 (46.6–77.2)
 Secondary VE 100.0 (NE-100.0) 64.3 (56.1–71.0) 66.1 (55.0–74.8) 100.0 (85.8–100.0) NA
Final blinded phase
 Primary VE 93.2 (91.0–94.8) 67.0 (58.9–73.5) 56.3 (51.3–60.8) NA NA
 Secondary VE 98.2 (92.8–99.6) 61.0 (54.4–66.7) 52.9 (47.1–58.1) NA NA

Abbreviations: NA, not applicable; NE, not estimable; VE, vaccine efficacy.

a

Primary and secondary end points differ by study; refer to Table 1 for definition of primary end points. Each study had multiple secondary end points; the results reported here refer to the key secondary end point listed in Table 2.